Benchmark Reiterates “Buy” Rating for Omnicell (NASDAQ:OMCL)

Benchmark reaffirmed their buy rating on shares of Omnicell (NASDAQ:OMCL) in a report issued on Monday, Benzinga reports. They currently have a $38.00 price objective on the stock.

Separately, StockNews.com raised shares of Omnicell from a hold rating to a buy rating in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus target price of $42.20.

Omnicell Price Performance

Omnicell stock opened at $27.52 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The firm has a fifty day simple moving average of $28.92 and a two-hundred day simple moving average of $29.43. Omnicell has a twelve month low of $25.12 and a twelve month high of $69.32.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.17. The business had revenue of $246.15 million during the quarter, compared to the consensus estimate of $235.70 million. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. On average, research analysts predict that Omnicell will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently modified their holdings of the company. EntryPoint Capital LLC increased its position in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the period. CWM LLC increased its position in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after buying an additional 1,236 shares during the period. Benjamin Edwards Inc. increased its position in shares of Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after buying an additional 868 shares during the period. Strs Ohio increased its position in shares of Omnicell by 28.2% during the fourth quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after buying an additional 1,100 shares during the period. Finally, Aristides Capital LLC purchased a new position in shares of Omnicell during the fourth quarter valued at about $269,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.